XML 28 R16.htm IDEA: XBRL DOCUMENT v3.25.2
Earnings Per Share
 6 Months Ended
Jun. 30, 2025
Earnings Per Share [Abstract]  
Earnings Per Share
Note 9 — Earnings Per Share
 
Basic earnings per share are based on the weighted average number of common shares outstanding for the period. Diluted earnings per share are based on the weighted average number of common shares and potentially dilutive common shares outstanding. Unvested restricted shares (608,954 as of June 30, 2025 and 138,633 as of June 30, 2024) are excluded from weighted average shares outstanding. Potential common shares outstanding principally include stock options, RSUs and warrants, excluding any potentially dilutive shares convertible at a price higher than the closing price of our stock at the end of each reporting period. The following table shows the computation of basic and diluted earnings per share for the three and six months ended June 30, 2025, and 2024 (in thousands, except per share amounts):
 

  
Three Months Ended
    
Six Months Ended
  
   
June 30,
    
June 30,
  
   
2025
    
2024
    
2025
    
2024
  
Numerator:
                        
Net (loss)
                        
   
$
(3,621
)
  
$
(3,830
)
  
$
(7,300
)
  
$
(8,121
)
Denominator:
                                
Weighted-average basic shares outstanding
    
3,660
      
3,593
      
3,660
      
3,593
  
Effect of dilutive securities
    
—
      
—
      
—
      
—
  
Weighted-average diluted shares
    
3,660
      
3,593
      
3,660
      
3,593
  
                                 
Basic (loss) per share
  
$
(0.99
)
  
$
(1.07
)
  
$
(1.99
)
  
$
(2.26
)
Diluted (loss) per share
  
$
(0.99
)
  
$
(1.07
)
  
$
(1.99
)
  
$
(2.26
)
 
We incurred a net loss for the three and six months ended June 30, 2025 and 2024; therefore, all potentially dilutive securities representing shares of common stock (248,488 at June 30, 2025 and 305,781 at June 30, 2024) were excluded from the computation of diluted earnings per share, because their effect would have been antidilutive.